Worsening of Lymphopenia during Apremilast Treatment

Apremilast is an oral phosphodiesterase IV inhibitor recently registered for the treatment of psoriasis and psoriatic arthritis in Switzerland and other countries. Even though it offers only moderate efficacy compared to biologics, many patients prefer drugs given by the oral route. Apremilast is fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolios, Antonios G.A., French, Lars E., Navarini, Alexander A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126611/
https://www.ncbi.nlm.nih.gov/pubmed/27920684
http://dx.doi.org/10.1159/000452321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126611/
https://www.ncbi.nlm.nih.gov/pubmed/27920684
http://dx.doi.org/10.1159/000452321

Ejemplares similares